Lamivudine ViiV - opinion on medicine for use outside EU

lamivudine

Overview

The opinion for Lamivudine ViiV for use outside the European Union has been withdrawn at the request of the opinion holder.

Lamivudine ViiV : Medicine overview

Reference Number: EMA/629364/2010

Product information

Lamivudine ViiV : Product information

Latest procedure affecting product information:H-W-673-WS-755

17/09/2015

Product information documents contain:

• Annex I - Summary of product characteristics
• Annex IIA - Manufacturer responsible for batch release
• Annex IIB - Recommendations to the opinion holder - conditions of use
• Annex IIIA - Labelling
• Annex IIIB - Package leaflet

Lamivudine ViiV : All presentations

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Lamivudine is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (HIV) infected adults and children.

Opinion details

Product details

• Name of medicine:
  Lamivudine ViiV
• EMA opinion number:
  H/W/673
• Opinion status:
  Withdrawn opinion
• Active substance:
  lamivudine
• International non-proprietary name (INN) or common name:
  lamivudine
• Therapeutic area (MeSH):
  HIV Infections
• Anatomical therapeutic chemical (ATC) code:
  J05AF05

Publication details

• Date of opinion:
  17/11/2005

Assessment history

Lamivudine ViiV : Procedural steps taken and scientific information after opinion

Lamivudine ViiV : Procedural steps taken before scientific opinion

Lamivudine ViiV : Scientific discussion

Lamivudine ViiV: Cessation of manufacture - Public statement

Reference Number: EMA/847375/2015